The combination of lartesertib with the ATR inhibitor gartisertib resulted in complete tumor growth inhibition in the MiaPaCa2 pancreatic cancer model and led to almost complete tumor regression in the acute myeloid leukemia model Mv4.11 (17). Here, ATR is linked to neoplasm.